Similarly, human data from the second multicentre oscillatory ARDS trial (MOAT II) showed a trend towards a reduction in mortality at 90 days, although the study was not powered to investigate this.
← all excerpts
22nd International Symposium on Intensive Care and Emergency Medicine, Brussels, Belgium, 19-22 March 2002.
1
—
—